Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 19/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8436513 | 0.92 | CXCR3 (0.69) | CXCR3ALDH1A1 | |
| SCHEMBL13291637 | 0.85 | CXCR3 (0.49) | CXCR3 | |
| SCHEMBL12829861 | 0.83 | CXCR3 (0.88) | CXCR3 | |
| SCHEMBL16152253 | 0.83 | CXCR3 (0.58) | CXCR3 | |
| SCHEMBL14622633 | 0.81 | CXCR3 (0.51) | CXCR3 | |
| SCHEMBL14264700 | 0.79 | CXCR3 (0.63) | CXCR3 | |
| SCHEMBL12464100 | 0.77 | CXCR3 (0.67) | CXCR3 | |
| SCHEMBL13633585 | 0.76 | CXCR3 (0.57) | CXCR3 | |
| SCHEMBL14264691 | 0.75 | CXCR3 (0.62) | CXCR3ALDH1A1LMNA | |
| SCHEMBL14621270 | 0.75 | CXCR3 (0.92) | CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246168-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246168-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-08-31 | — | — | US | disclosed |
| US-9649312-B2 | Compositions and methods of treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649312-B2 | Compositions and methods of treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160324858-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20160324858-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-8852937-B2 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130190495-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190495-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-8349853-B2 | Detection defect in gene expression of hedgehog gene; diagnosis of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349853-B2 | Detection defect in gene expression of hedgehog gene; diagnosis of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-01-08 | — | — | US | disclosed |
| EP-1425016-B1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-2116248-A1 | Compositions and Methods of Treatment of Cancer | Minerva Biotechnologies Corporation (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080207740-A1 | tert-Butyl {4-[(4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino]-cyclohexyl}-methyl-carbamate; hedgehog pathway agonists; to modulate proliferation or differentiation in a cell or tissue in vivo or vitro; alopecia; angiogenesis; wound healing; alzheimer's disease; to inhibit aging effects on skin | CURIS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
| US-20050070578-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324858-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MUC1, TP53, BRCA1 | CXCR3 109/4885ALDH1A1 833/4885LMNA 2567/4885 |
| US-20080207740-A1 | tert-Butyl {4-[(4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino]-cyclohexyl}-methyl-carbamate; hedgehog pathway agonists; to modulate proliferation or differentiation in a cell or tissue in vivo or vitro; alopecia; angiogenesis; wound healing; alzheimer's disease; to inhibit aging effects on skin | SHH, GLI1, SMO | CXCR3 941/4885ALDH1A1 2174/4885LMNA 4560/4885 |
| US-20050070578-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | CXCR3 794/4885ALDH1A1 1212/4885LMNA 4848/4885 |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MUC1, CD44, TP53 | CXCR3 1257/4885ALDH1A1 674/4885LMNA 2816/4885 |
| US-20130190495-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MUC1, TP53, BRCA1 | CXCR3 109/4885ALDH1A1 833/4885LMNA 2567/4885 |
| US-20170246168-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MUC1, TP53, BRCA1 | CXCR3 109/4885ALDH1A1 833/4885LMNA 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.